Worldwide Chronic Idiopathic Constipation Market 2018 Research Report implements an exhaustive study on Market Research Future. This Report Cover Key Market Driver, market size, growth rate, opportunities, market Dynamics and Overall Analysis. And also cover the other information such as Chronic Idiopathic Constipation Market trends, Prominent players, chapter-wise Description followed by various user perceptions and Forecast till 2023.
Chronic Idiopathic Constipation Market – Insights
Chronic Idiopathic Constipation market is expected to grow at a CAGR of 7.4% during the forecast period. In simple terms, constipation can be defined as the reduced stool frequency which could be less than three times per week. It can also be said to have difficulty passing stool. Chronic idiopathic constipation is a health condition in which the patient suffers from chronic symptoms of constipation. Moreover, constipation is one of the most frequently occurring Gastrointestinal (GI) complaints or problem.
According to a report by the World Gastroenterology Organization, 35 to 40 % of the world’s total population is suffering from acute or chronic GI complication. The increasing number of patients having GI diseases and disorders due to change in dietary pattern is the major factor for driving the global chronic idiopathic constipation market. According to reports from, Allergan and Ironwood Pharmaceuticals, Inc. major symptoms of constipation are infrequent stools (having a bowel movement less than three times a week), difficulty passing stools, which includes straining to have a bowel movement, not completely emptying bowels after a movement, hard or lumpy stools, gas pain, abdominal discomfort, and others.
Top Vendors of Chronic Idiopathic Constipation Market Research Report:
Some of the key players in this market are Actavis (U.S.), Chugai Pharmaceutical (Japan), Ferring International Center S.A.(Switzerland), Synergy Pharmaceuticals (U.S.), Pfizer Inc (U.S.), GlaxoSmithKline (U.K.), Sanofi (France), Bayer (Germany), Salix Pharmaceuticals Ltd (U.S.), Sucampo Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals (U.S.), Progenics Pharmaceuticals (U.S.), F. Hoffmann-La Roche AG (Switzerland), Boehringer Ingelheim GmbH (Germany), Daewoong Co. Ltd.(South Korea), Synergy Pharmaceuticals, Inc. (U.S.) and others.
Avail Premium Sample Report @ https://www.marketresearchfuture.com/sample_request/5931 .
Chronic Idiopathic Constipation Market – Regional Analysis:
The American chronic idiopathic constipation market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven due to the increasing prevalence of chronic constipation and growing investment in healthcare. Furthermore, the U.S. is the largest market in North America owing to the presence of a large number of market players manufacturing medications for constipation. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for diagnostic and treatment methods. South America is expected to be the fastest growing market due to technological advancements for diagnosis and increasing demand for treatment options of GI diseases.
The European chronic idiopathic constipation market exhibits growth with an increasing emphasis on the diagnosis and treatment of GI diseases and others. Moreover, Germany and the U.K. are the major contributors to the growth of the market. Additionally, the increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market.
Asia Pacific is expected to be the fastest growing market whose growth is attributed to a huge demand for diagnostic tests and increasing focus on early diagnosis and treatment of GI diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among adults, and addiction to smoking.
Chronic Idiopathic Constipation Market – Segmentation:
The global chronic idiopathic constipation market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the market is segmented into blood tests, sigmoidoscopy, colonoscopy, balloon expulsion test, anorectal manometry, colonic transit study, defecography, and others.
On the basis of treatment, the market is segmented into drug and surgery. Drugs are further segmented into acid neutralizers, laxatives and antidiarrheal, antiemetics, antiulcer, lubiprostone (amitiza) and linaclotide (linzess), misoprostol (Cytotec), colchicine/probenecid (Col-Probenecid) and Onabotulinumtoxin A (also called botulinum toxin type A or Botox), and others.
On the basis of end-user, the market is segmented into hospitals, gastroenterology clinics, diagnostic centers and others.
TOC of Chronic Idiopathic Constipation Market Research Report – Forecast to 2023:
1. Report Prologue
2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
Avail stunning Discount @ https://www.marketresearchfuture.com/check-discount/5931 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312